Inventory, net |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2011 | |||||||||||||||||||||||||||||||||||||||
Inventory, net |
From
time to time, we capitalize certain inventory costs associated with
our Lymphoseek®
product prior to regulatory approval and product launch based on
management’s judgment of probable future commercial use and
net realizable value of the inventory. We could be
required to permanently write down previously capitalized costs
related to pre-approval or pre-launch inventory upon a change in
such judgment, due to a denial or delay of approval by regulatory
bodies, a delay in commercialization, or other potential
factors. Conversely, our gross margins may be favorably
impacted if some or all of the inventory previously expensed
becomes available and is used for commercial sale.
During
the nine-month period ended September 30, 2011, we capitalized
$213,000 of inventory costs associated with our Lymphoseek
product. During the three-month periods ended September
30, 2011 and 2010, and the nine-month period ended September 30,
2010, we did not capitalize any such costs. During the
nine-month period ended September 30, 2010, we expensed $351,000 of
previously capitalized pharmaceutical materials to research and
development as they were no longer considered to be usable in the
production of future saleable final drug product
inventory.
The
components of net inventory as of September 30, 2011 and December
31, 2010 are as follows:
We
estimate a reserve for obsolete inventory based on
management’s judgment of probable future commercial use,
which is based on an analysis of current inventory levels,
estimated future sales and production rates, and estimated shelf
lives. Based on our evaluations, we did not record a
reserve for obsolete inventory as of September 30, 2011 or December
31, 2010.
|